NCT05541328View on ClinicalTrials.gov

Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel

CompletedOBSERVATIONAL
Enrollment

169

Participants

Timeline

Start Date

February 3, 2020

Primary Completion Date

February 5, 2021

Study Completion Date

February 5, 2021

Conditions
Diffuse Large B-cell Lymphoma
Interventions
OTHER

Tisagenlecleucel

The trial cohort is defined as the cohort of patients enrolled in JULIET who were assigned to receive tisagenlecleucel infusion

Trial Locations (1)

07936-1080

Novartis Investigative Site, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY